First nationwide human immunology registry for infectious disease research

NewsGuard 100/100 Score

RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide human immunology registry for infectious disease research. The new registry was developed to help clinicians and researchers better understand the human immune response to emerging and re-emerging infectious diseases.

Details about the registry:

http://www.remedymd.com/cer100/human_immunology.html

Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s human immunology registry will help researchers develop new vaccines to protect against infectious diseases such as:

  • Influenza
  • Dengue fever
  • Anthrax
  • Hepatitis C

and help researchers understand how the immune system develops its own protections and how harmless microorganisms in the lungs, intestines and other mucosal surfaces protect against harmful microbes that enter the body through these sites.

The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

“Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies,” said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD’s new human immunology registry leverages existing clinical and EHR data and includes a comprehensive set of electronic data collection (EDC) forms that are specific to immunology research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying novel conclusions as they search for the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of immunology researchers. All institutions involved in comparative effectiveness research are invited to visit: http://www.remedymd.com/cer100/human_immunology.html.

RemedyMD Resources:

Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html

Ways to leverage Human Immunology Registry: http://www.remedymd.com/cer100/human_immunology.html

Comparative Effectiveness Research: www.remedymd.com/cer_home.html

Disease Registry Software: www.remedymd.com/registries_home.html

Source: RemedyMD

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis